Summary
Observations were made in 5 healthy subjects who exercised before and 1, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg long acting propranolol and 400 mg sotalol. Blood samples were obtained before and at 1, 2, 3, 6, 8, 10 and 24 h after drug administration and assayed for drug concentration. Although the plasma concentration of oxprenolol after S. R. oxprenolol was significantly less at 1 and 2 h and significantly greater at 24 h than after conventional oxprenolol, there was little difference between the effects of the two drugs on an exercise tachycardia. The plasma level of propranolol and the reduction in an exercise tachycardia after L. A. propranolol increased slowly to reach a peak at 6 h and then declined gradually to 24 h. The maximum plasma concentration and effect after sotalol occurred at 3 h and then declined with an elimination half-life of 12.1 h. At 24 h the percentage reduction in an exercise tachycardia was 8.3±2.5 after oxprenolol, 10.0±2.3 after S. R. oxprenolol, 18.0±3.2 after L. A. propranolol and 14.7±3.4% after sotalol.
Similar content being viewed by others
References
Aellig WH (1978) Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers. Eur J Clin Pharmacol 14: 167–169
Brown HC, Carruthers SG, Kelly JG, McDevitt DG, Shanks RG (1976) Observations of the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol 9: 367–372
Dawes CP, Kendall MJ, Welling PG (1979) Bioavailability of conventional and slow-release oxprenolol in fasted and non-fasted individuals. Br J Clin Pharmacol 7: 299–302
Degen PH, Riess W (1976) Simplified method for the determination of oxprenolol and other β-receptor blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr 121: 72–75
Garrett ER, Schnelle K (1971) Separation and spectrofluorometric assay of the beta-adrenergic blocker sotalol from blood and urine. J Pharm Sci 60: 833–839
Gatley MS (1968) To be taken as directed. J R Coll Gen Pract 16: 39–44
Leahey WH, Neill JD, Varma MPS, Shanks RG (in press 1979) Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol
McAinsh J, Baber NS, Smith R, Young J (1978) Pharmacokinetic and pharmacodynamic studies with long acting propranolol. Br J Clin Pharmacol 6: 115–211
McDevitt DG, Shanks RG (1977) Evaluation of once daily sotalol administration in man. Br J Clin Pharmacol 4: 153–156
McDevitt DG, Brown HC, Carruthers SG, Shanks RG (1977) Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther 21: 556–566
Mason WD, Winer N (1976) Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther 20: 401–412
Shand DG, Nuckolls EM, Oates JA (1970) Plasma propranolol levels in adults: with observations in four children. Clin Pharmacol Ther 11: 112–120
West MJ, Kendall MJ, Mitchard M, Faragher EB (1976) A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects. Br J Clin Pharmacol 3: 439–443
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leahey, W.J., Neill, J.D., Varma, M.P.S. et al. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol 17, 419–424 (1980). https://doi.org/10.1007/BF00570158
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570158